Global Cell and Gene Therapy Market

Cell and Gene Therapy Market Size, Share, Growth Analysis, By Therapy Type (Cell Therapy, Gene Therapy), By Therapeutic class (Cardiovascular Disease, Cancer), By Delivery Method, By End-Users, By Region - Industry Forecast 2024-2031

Report ID: SQMIG35G2300 | Region: Global | Published Date: November, 2024
Pages: 194 | Tables: 96 | Figures: 72

Cell and Gene Therapy Market Competitive Landscape

Cell and gene therapy providers should focus on increasing the affordability and accessibility of their offerings to maximize business growth in the future. Investing in research to foster innovation will be a key strategy for new as well as established cell and gene therapy companies across the study period and beyond. Targeting emerging markets will also offer good return on investment for all cell and gene therapy providers in the future.

Top Player’s Company Profiles

  • Alnylam Pharmaceuticals Inc. (US) 
  • Amgen Inc. (US) 
  • Biogen Inc. (US) 
  • CORESTEM Inc. (US) 
  • Helixmith Co. Ltd. (South Korea) 
  • JCR Pharmaceuticals Co. Ltd. (Japan) 
  • Kolon TissueGene Inc. (South Korea) 
  • Novartis AG (Switzerland) 
  • Pfizer Inc. (US) 
  • Gilead Sciences, Inc. (US) 
  • Sangamo Therapeutics, Inc. (US) 
  • Bluebird Bio, Inc. (US) 
  • Zymeworks Inc. (Canada) 
  • CRISPR Therapeutics AG (Switzerland) 
  • Celyad Oncology SA (Belgium) 
  • Atara Biotherapeutics, Inc. (US) 
  • Athenex, Inc. (US) 
  • Bristol Myers Squibb (US) 
  • Kyowa Kirin (Japan) 
  • Sanofi (France)

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Cell and Gene Therapy Market size was valued at USD 17.7 billion in 2022 and is poised to grow from USD 20.97 billion in 2023 to USD 81.55 billion by 2031, growing at a CAGR of 18.50% during the forecast period (2024-2031).

Cell and gene therapy providers should focus on increasing the affordability and accessibility of their offerings to maximize business growth in the future. Investing in research to foster innovation will be a key strategy for new as well as established cell and gene therapy companies across the study period and beyond. Targeting emerging markets will also offer good return on investment for all cell and gene therapy providers in the future. 'Alnylam Pharmaceuticals Inc. (US) ', 'Amgen Inc. (US) ', 'Biogen Inc. (US) ', 'CORESTEM Inc. (US) ', 'Helixmith Co. Ltd. (South Korea) ', 'JCR Pharmaceuticals Co. Ltd. (Japan) ', 'Kolon TissueGene Inc. (South Korea) ', 'Novartis AG (Switzerland) ', 'Pfizer Inc. (US) ', 'Gilead Sciences, Inc. (US) ', 'Sangamo Therapeutics, Inc. (US) ', 'Bluebird Bio, Inc. (US) ', 'Zymeworks Inc. (Canada) ', 'CRISPR Therapeutics AG (Switzerland) ', 'Celyad Oncology SA (Belgium) ', 'Atara Biotherapeutics, Inc. (US) ', 'Athenex, Inc. (US) ', 'Bristol Myers Squibb (US) ', 'Kyowa Kirin (Japan) ', 'Sanofi (France)'

Advancements in Gene Technologies

Demand for Combination Therapies: Popularity of combination therapies is increasing around the world owing to their high efficacy in treating a patient. Cell and gene therapy companies should focus on developing novel combination therapies that combine the benefits of gene and cell therapies to give the best possible treatment for patients suffering from various disease indications.

North America is projected to account for a dominant share of the global cell and gene therapy market owing to high investments in medical R&D in this region. High healthcare expenditure, presence of a developed healthcare infrastructure, and rising acceptance of novel therapies are key factors that contribute to the dominance of this region. The United States is slated to be the leading market for cell and gene therapy providers looking to dominate North American market. Supportive government initiatives and funding to boost medical research will also help promote market development in this region.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Feedback From Our Clients

Global Cell and Gene Therapy Market

Report ID: SQMIG35G2300

$5,300
BUY NOW GET FREE SAMPLE